Racial Disparities in Lung Cancer: Part 3 of a Special Series
In part 3 of this series, we interviewed Samuel Cykert, MD, who helped build a system-based intervention to reduce racial gaps and improve care for all patients with lung cancer.
Lung Cancer
Racial Disparities in Lung Cancer: Part 2 of a Special Series
In part 2 of this 3-part series, the recent State of Lung Cancer report by the American Lung Association, which included state-level and national-level data on lung cancer in people of color for the first time.
Tiragolumab Gets Breakthrough Therapy Status for PD-L1-High NSCLC
Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.
COVID-19 Pandemic Has Disrupted Lung Cancer Screenings
COVID-19 has caused significant disruption in lung cancer screening.
Racial Disparities in Lung Cancer: Part 1 of a Special Series
A sizable body of research has long shown racial disparities in treatment and survival between Black and White patients with lung cancer.
Nivolumab No Longer FDA-Approved for Small Cell Lung Cancer
In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.
Lorlatinib Under Review for Previously Untreated ALK-Positive NSCLC
The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.
SARS-CoV-2 Infection Rate Low in Patients Receiving Antitumor Therapy
Less than 1 percent of patients receiving antitumor treatment between Jan. 15 and May 4, 2020, developed COVID-19
Osimertinib Approved as Adjuvant Therapy for Early-Stage EGFR-Mutant NSCLC
The approval was based on data from the double-blind, placebo-controlled phase 3 ADAURA study.
Oral Microbiome Linked to Lung Cancer Risk in Never-Smokers
Lower alpha diversity of the oral microbiota is associated with an increased risk for lung cancer in never-smokers, and the abundance of specific taxa are associated with altered risk.
-
Loading...
-
Loading...
Next post in Lung Cancer
